Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million infections and 1 million deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here, we examine the properties of highly potent human monoclonal antibodies (hu-mAb...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of experimental medicine 2021-03, Vol.218 (3)
Hauptverfasser:	Schäfer, Alexandra, Muecksch, Frauke, Lorenzi, Julio C C, Leist, Sarah R, Cipolla, Melissa, Bournazos, Stylianos, Schmidt, Fabian, Maison, Rachel M, Gazumyan, Anna, Martinez, David R, Baric, Ralph S, Robbiani, Davide F, Hatziioannou, Theodora, Ravetch, Jeffrey V, Bieniasz, Paul D, Bowen, Richard A, Nussenzweig, Michel C, Sheahan, Timothy P
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal, Murine-Derived - immunology Antibodies, Monoclonal, Murine-Derived - pharmacology Antibodies, Neutralizing - immunology Antibodies, Neutralizing - pharmacology Antibodies, Viral - immunology Antibodies, Viral - pharmacology Betacoronavirus - immunology Cell Line Coronavirus Infections - immunology Coronavirus Infections - therapy COVID-19 Female Humans Infectious Disease and Host Defense Mesocricetus Mice Mice, Inbred BALB C Pandemics Pneumonia, Viral - immunology Pneumonia, Viral - therapy SARS-CoV-2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!